

Contents

Preface, ix

Chapter 1: Research malpractice and negligence, 1

- 1.1 Background, 1
- 1.2 Drugs: brief description of definitions, 4
- 1.3 Brief overview: conduct of clinical trials, 5
- 1.4 Medical devices, 6
- 1.5 Research malpractice: the basics, 7
- 1.6 Negligence actions and research: interesting aspects of medical research negligence cases, 8

Chapter 2: Duty of care: understanding the legal differences between medical treatment and medical research, 23

- 2.1 Establishing duty of care, 23
- 2.2 Do sponsors have a legal duty?, 27

Chapter 3: Establishing standard of care and violation of standard of care, 33

- 3.1 Research malpractice and using expert testimony to establish the standard of care, 34
- 3.2 Lessons learned from surgical innovation cases, 35
- 3.3 Standard of care and informed consent cases, 36

Chapter 4: Informed consent in clinical research, 37

- 4.1 Basics on informed consent in the clinical treatment setting: background, 37
- 4.2 Informed consent as applied to the research setting, 40
- 4.3 Informed consent and federal regulations, 42
- 4.4 Case law and federal regulations, 43
- 4.5 Clinical trials and pediatric patients, 46

vi **Contents**

Chapter 5: Liability issues for institutional review boards (IRBs) and data safety monitoring boards (DSMBs), 55

- 5.1 Liability for negligence, 56
- 5.2 Standard of care, 57
- 5.3 Proximate cause and damages, 59
- 5.4 Defense, 60
- 5.5 Practical considerations: the need for indemnification, 62
- 5.6 Special considerations for DSMBs, 62

Chapter 6: Legal aspects of financial conflicts of interest in clinical trials, 65

- 6.1 Overview, 66
- 6.2 Legislative background: road to creating financial conflicts of interest, 68
- 6.3 Financial conflicts of interest: evidence that financial conflicts of interest are problematic, 69
- 6.4 Regulations/legislation, 70
- 6.5 Litigation involving financial conflicts of interest in clinical trials, 74
- 6.6 Applying novel legal theories to financial conflicts of interest cases, 79
- 6.7 Other clinical trial cases involving financial conflicts of interest claiming constitutional violations, 81

Chapter 7: Disclosure of clinical trial information: legal ramifications of withholding study results, 87

- 7.1 GlaxoSmithKline, 89
- 7.2 Vioxx and Merck, 91
- 7.3 Government and other clinical trial disclosure requirements, 97
- 7.4 Medical journal editors and disclosure of clinical trial information, 98

Chapter 8: Clinical trials and insider trading, 105

- 8.1 Purpose of insider trading laws, 105
- 8.2 Proving insider trading, 106
- 8.3 Penalties, 108
- 8.4 Insider trading cases and clinical trials, 108
- 8.5 Beware: investigators and relationships with the investment industry—a risk of recent vintage, 111
- 8.6 Setting the stage, 113

Chapter 9: Clinical trials and criminal law, 117

- 9.1 How clinical trial investigators have been implicated in criminal acts, 119
- 9.2 False Claims Act cases and health-care fraud, 120
- 9.3 Clinical trial False Claims Act cases, 122
- 9.4 Enforcement of the False Claims Act against institutions, 130
- 9.5 Anti-kickback law, 132
- 9.6 Health-care fraud, 138
- 9.7 Mail and wire fraud/making false statements to government officials, 141
- 9.8 Proposed new FDA rule, 143

Chapter 10: Clinical trial contracts, 145

- 10.1 Key terms/scope of study, 146
- 10.2 Costs/payments, 147
- 10.3 Data, 147
- 10.4 Intellectual property, 148
- 10.5 Indemnification/injuries, 148
- 10.6 Publications, 149
- 10.7 Various sundry provisions, 149

Appendix A: Glossary of common terms used in connection with clinical trials, 151

Appendix B: Research involving human subjects, 163

Appendix C: Best pharmaceuticals for Children Act, 173

Appendix D: Pediatric research Equity Act of 2003, 193

Appendix E: Title 21–food and drugs: additional safeguards for children in clinical investigations, 203

Appendix F: Proposed standardized/harmonized clauses for clinical trial agreements, 209

viii **Contents**

**Appendix G: Responsibility of applicants for promoting
objectivity in research for which public health
service funding is sought and responsible
prospective contractors, 225**

Index, 257